Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions to ask one cell type to become another.
Mirugen has raised $2.9M in total funding. The most recent round was Seed. The last funding was announced in August 2025.
Mirugen's investors include Brandon Capital, Tin Alley Ventures, Genesis Pre-Seed Fund.
Mirugen is headquartered in Melbourne, Australia.
Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions to ask one cell type to become another.
Mirugen is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mirugen — Funding & Investors." VCBacked, August 13, 2025, https://www.vcbacked.co/company/mirugen. Accessed September 30, 2026.
VCBacked. (2025). Mirugen — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/mirugen
{{cite web |title=Mirugen — Funding & Investors |url=https://www.vcbacked.co/company/mirugen |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated